Expert Exchange 2022: Data-Driven Debates on the Evolving Bladder Cancer Landscape: Harnessing Novelty to Improve Outcomes
In this Expert Exchange-based format, activity attendees will be immersed in a lively and dynamic discussion between key thought leaders in the world of bladder cancer. Using clinical cases, two top experts will discuss current hot topics across the disease continuum, and in doing so, provide answers to pivotal clinical questions.
This activity is designed to meet the educational needs of medical oncologists, surgical oncologists, urologists, and other healthcare professionals that care for patients with bladder cancer.
- Appraise the expanding clinical trial evidentiary base across all stages of the bladder cancer disease continuum, including newly-approved indications, recently-reported data, and current consensus guideline recommendations for treatment of NMIBC, MIBC, and locally advanced/mUC.
- Examine the evolving bladder cancer management calculus, with a focus on evidence-based treatment sequencing strategies and/or combinatorial regimens incorporating platinum chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates.
- Design evidence-supported treatment plans for patients with bladder cancer, both in first-line and post-progression, by effectively integratin consensus guideline recommendations with patient-centric factors (i.e., performance status, renal function, PD-L1 expression, FGFR mutation, cytopathology, urinary markers, etc.).
- Identify immune-mediated adverse events (imAEs) that may occur in patients with bladder cancer receiving immune checkpoint inhibitors either as monotherapy or in combination, and implement adaptive imAE anticipation, recognition, and management strategies.
Robert Dreicer, MD, MS, MACP, FASCO (Moderator)
Associate Director for Clinical Research
Deputy Director, University of Virginia Cancer Center
Section Head, Medical Oncology
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Sam S. Chang MD, MBA
Professor, Department of Urology
Patricia and Rodes Hart Professor of Urologic Surgery
Chief Surgical Officer
Chief, Division of Urologic Oncology
Vanderbilt Ingram Cancer Center
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of a CE Request Form, statements of credit for physicians will be issued within 30 business days.
Supported through independent educational grants from AstraZeneca and Merck.
Not an official event of the 2022 Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2022 Genitourinary Cancers Symposium.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation